Atlanta, if weight loss has felt harder after 40, or if diet and exercise no longer move the needle, you’re not alone. Semaglutide’s FDA-approved path offers a medical way forward: doctor-led, monitored, and designed to restore energy, confidence, and control. This guide distills the evidence and shows how a clinical plan can work with your biology.
The Clinical Evolution of Semaglutide
Key Regulatory Milestones
2017 — Ozempic®
The FDA approved Ozempic for Type 2 Diabetes, establishing semaglutide’s foundation.
Read Notice2021 — Wegovy®
Wegovy earned approval for chronic weight management with sustained outcomes.
See Data2024 — CV Indication
The label gained a cardiovascular indication to reduce major events in at-risk adults.
View AnnouncementHow Semaglutide Works
Although motivation matters, biology often decides the outcome. Semaglutide mimics a natural hormone (GLP-1) to slow gastric emptying, increase satiety, and improve glycemic control. As a result, cravings fade, portions shrink, and post-meal glucose spikes decline—allowing lifestyle changes to finally “stick.”
Who Qualifies for Treatment
Wegovy (semaglutide 2.4 mg) is FDA-indicated for adults with a BMI ≥ 30, or a BMI ≥ 27 with a weight-related condition such as hypertension or Type 2 Diabetes. We confirm eligibility privately and personalize every aspect of your plan during a thorough consultation.